1101120-80-2

Usage

Uses

Used in Organic Synthesis:
5-cyano-2-fluorobenzene-1-sulfonyl chloride is utilized as a reagent for introducing the sulfonyl chloride functional group into various organic molecules. Its unique structure allows for the creation of new compounds with specific properties, making it a valuable tool in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 5-cyano-2-fluorobenzene-1-sulfonyl chloride serves as a key intermediate for the preparation of sulfonyl chloride-containing compounds. These intermediates are crucial for the synthesis of various drugs, contributing to the development of novel therapeutic agents.
Used in Agrochemical Production:
5-cyano-2-fluorobenzene-1-sulfonyl chloride is an important building block in the production of agrochemicals. Its incorporation into agrochemical compounds can enhance their effectiveness in pest control and crop protection, thereby supporting sustainable agriculture.
Used in Specialty Chemicals:
5-cyano-2-fluorobenzene-1-sulfonyl chloride also plays a significant role in the manufacturing of specialty chemicals, where its unique properties can be harnessed to create high-performance materials for various industrial applications.

Upstream product

• 859855-53-1 3-amino-4-fluorobenzonitrile 
• 1009-35-4 4-fluoro-3-nitrobenzonitrile 

Downstream Products

• 1101119-45-2 5-cyano-N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-2-fluoro-N-methylbenzenesulfonohydrazide 
• 1101119-43-0 N'-((5-bromopyrazolo[1,5-a]pyridin-3-yl)methylene)-N-methyl-2-(2-morpholinoethoxy)-5-nitrobenzenesulfonohydrazide hydrochloride 
• 1101119-49-6 5-cyano-N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-2-((2-(dimethylamino)ethyl)(methyl)amino)-N-methylbenzenesulfonohydrazide hydrochloride 
• 1101119-53-2 5-cyano-N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-N-methyl-2-(2-morpholinoethoxy)benzenesulfonohydrazide hydrochloride 
• 1101119-38-3 N'-((5-bromopyrazolo[1,5-a]pyridin-3-yl)methylene)-2-fluoro-N-methyl-5-nitrobenzenesulfonohydrazide 
• 1448452-06-9 4-(4-chlorophenoxy)-3-sulfamoylbenzonitrile 
• 1448452-05-8 4-(4-fluorophenoxy)-3-sulfamoylbenzonitrile 
• 1448452-04-7 4-(2-methylphenoxy)-3-sulfamoylbenzonitrile 
• 1448452-03-6 4-(3-methylphenoxy)-3-sulfamoylbenzonitrile 
• 1448452-02-5 4-(4-methylphenoxy)-3-sulfamoylbenzonitrile 
• 1448452-44-5 N-pentyl-N'-[2-(4-fluorophenylamino)-5-cyanobenzenesulfonyl]urea 
• 1448452-43-4 N-tert-Bbtyl-N'-[2-(4-fluorophenylamino)-5-cyanobenzenesulfonyl]urea 
• 1448452-42-3 N-isopropyl-N'-[2-(4-fluorophenylamino)-5-cyanobenzenesulfonyl]urea 
• 1448452-41-2 N-pentyl-N'-[2-(4-methylphenylamino)-5-cyanobenzenesulfonyl]urea 

Relevant academic research and scientific papers

ACLY INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitors

As part of our investigation into pyrazolo[1,5-a]pyridines as novel p110α selective PI3 kinase inhibitors, we report a range of analogues with improved aqueous solubility by the addition of a basic amine. The compounds demonstrated comparable p110α potency and selectivity to earlier compounds but with up to 1000× greater aqueous solubility, as the hydrochloride salts. The compounds also displayed good activity in a cellular assay of PI3 kinase activity.

Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5- cyanobenzenesulfonylureas as novel thromboxane A2 receptor antagonists

New series of original 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas were synthesized and evaluated as thromboxane A2 receptor (TP receptor) antagonists. A functional pharmacological test was used, which consisted of measuring the inhibition

PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY

Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.